Abstract

This is a pilot, open label-clinical trial designed to test the toxicity and potential efficacy of a new immunoablative and bone marrow suppressive combination regimen prior (preparative phase) to stem cell transplantation in patients with rapidly progressing cutaneous scleroderma.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research and Development Contracts (N01)
Project #
N01AR092239-002
Application #
6355501
Study Section
Project Start
1999-09-30
Project End
2003-09-29
Budget Start
2000-09-20
Budget End
2001-03-31
Support Year
Fiscal Year
2000
Total Cost
$494,890
Indirect Cost

  Institution

Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213

  Publications

Donnenberg, Albert D; Donnenberg, Vera S (2007) Rare-event analysis in flow cytometry. Clin Lab Med 27:627-52, viii
Hu, Paul Q; Oppenheim, Joost J; Medsger Jr, Thomas A et al. (2006) T cell lines from systemic sclerosis patients and healthy controls recognize multiple epitopes on DNA topoisomerase I. J Autoimmun 26:258-67
Hu, Paul Q; Fertig, Noreen; Medsger Jr, Thomas A et al. (2004) Molecular recognition patterns of serum anti-DNA topoisomerase I antibody in systemic sclerosis. J Immunol 173:2834-41
Hu, Paul Q; Fertig, Noreen; Medsger Jr, Thomas A et al. (2003) Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 48:1363-73
Meidenbauer, Norbert; Hoffmann, Thomas K; Donnenberg, Albert D (2003) Direct visualization of antigen-specific T cells using peptide-MHC-class I tetrameric complexes. Methods 31:160-71